About Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Scientists Identify Compound That can Stop Growth of Malaria Parasites

by Sheela Philomena on July 20, 2012 at 3:42 PM
Font : A-A+

 Scientists Identify Compound That can Stop Growth of Malaria Parasites

A key enzyme involved in survival of the parasite responsible for malaria has been discovered by scientists.

Tropical malaria is responsible for more than 1.2 million deaths annually. Severe forms of the disease are mainly caused by the parasite Plasmodium falciparum, transmitted to humans by female Anopheles mosquitoes. Malaria eradication has not been possible due to the lack of vaccines and the parasite's ability to develop resistance to most drugs.

Advertisement

An international team of scientists, led by researchers from the Department of Pediatrics at the University of California, San Diego School of Medicine, conducted high-throughput screening of nearly 350,000 compounds in the National Institutes of Health's Molecular Libraries Small Molecule Repository (MLSMR) to identify compounds that inhibit an enzyme which plays an important role in parasite development: Plasmodium falciparum glucose-6-phosphate dehydrogenase (PfG6PD) is essential for proliferating and propagating P. falciparum.

"The enzyme G6PD catalyzes an initial step in a process that protects the malaria parasite from oxidative stress in red blood cells, creating an environment in which the parasite survives," said senior author Lars Bode, PhD, assistant professor in the UCSD Department of Pediatrics, Division of Neonatology and the Division of Gastroenterology, Hepatology and Nutrition.
Advertisement

People with a natural deficiency in this enzyme are protected from malaria and its deadly symptoms, an observation that triggered the reported research.

The parasitic form of the enzyme (PfG6PD) is what contributes the majority of G6PD activity in infected red blood cells. Because the parasite lives in the blood of a malaria-infected person, the scientists aimed at identifying compounds that inhibit the parasitic form but not the human form of the enzyme.

"'We didn't want to interfere with the human form of the enzyme and risk potential side effects,"' Bode explained.

Scientific testing had previously been limited by a lack of recombinant PfG6PD. Team members in the lab of Katja Becker, PhD, at the Interdisciplinary Research Center at Justus-Liebig-University in Giessen, Germany produced the first complete and functional recombinant PfG6PD, and researchers led by Anthony Pinkerton, PhD, at Sanford-Burnham Medical Research Institute used it to identify the lead compound resulting from their efforts, ML276.

ML276 represents the first reported selective PfG6PD inhibitor, which stops the growth of malaria parasites in cultured red blood cells - even those parasites that developed resistance to currently available drugs.

"ML276 is a very promising basis for future drug design of new anti-malarial therapeutics," said Bode.

The findings are currently published in the online version of the Journal of Medicinal Chemistry.

Source: ANI
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Test your Knowledge on Heart Transplantation
Test Your Knowledge on Lung Transplantation
Baldness can be Cured and Prevented: let us see How!
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Malaria-water Malaria Mosquito Diseases Fever Malaria - Protection Strategies 

Most Popular on Medindia

Hearing Loss Calculator Calculate Ideal Weight for Infants Accident and Trauma Care Drug Interaction Checker Blood Pressure Calculator Loram (2 mg) (Lorazepam) Pregnancy Confirmation Calculator Color Blindness Calculator Selfie Addiction Calculator Iron Intake Calculator
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use